File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Metabonomics identifies serum metabolite markers of colorectal cancer

TitleMetabonomics identifies serum metabolite markers of colorectal cancer
Authors
Keywordscolorectal cancer
diagnostic markers
metabolomics/metabonomics
serum metabolites
Issue Date2013
Citation
Journal of Proteome Research, 2013, v. 12, n. 6, p. 3000-3009 How to Cite?
AbstractRecent studies suggest that biofluid-based metabonomics may identify metabolite markers promising for colorectal cancer (CRC) diagnosis. We report here a follow-up replication study, after a previous CRC metabonomics study, aiming to identify a distinct serum metabolic signature of CRC with diagnostic potential. Serum metabolites from newly diagnosed CRC patients (N = 101) and healthy subjects (N = 102) were profiled using gas chromatography time-of-flight mass spectrometry (GC-TOFMS) and ultraperformance liquid chromatography quadrupole time-of-flight mass spectrometry (UPLC-QTOFMS). Differential metabolites were identified with statistical tests of orthogonal partial least-squares-discriminant analysis (VIP > 1) and the Mann-Whitney U test (p < 0.05). With a total of 249 annotated serum metabolites, we were able to differentiate CRC patients from the healthy controls using an orthogonal partial least-squares-discriminant analysis (OPLS-DA) in a learning sample set of 62 CRC patients and 62 matched healthy controls. This established model was able to correctly assign the rest of the samples to the CRC or control groups in a validation set of 39 CRC patients and 40 healthy controls. Consistent with our findings from the previous study, we observed a distinct metabolic signature in CRC patients including tricarboxylic acid (TCA) cycle, urea cycle, glutamine, fatty acids, and gut flora metabolism. Our results demonstrated that a panel of serum metabolite markers is of great potential as a noninvasive diagnostic method for the detection of CRC. © 2013 American Chemical Society.
Persistent Identifierhttp://hdl.handle.net/10722/342448
ISSN
2023 Impact Factor: 3.8
2023 SCImago Journal Rankings: 1.299
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorTan, Binbin-
dc.contributor.authorQiu, Yunping-
dc.contributor.authorZou, Xia-
dc.contributor.authorChen, Tianlu-
dc.contributor.authorXie, Guoxiang-
dc.contributor.authorCheng, Yu-
dc.contributor.authorDong, Taotao-
dc.contributor.authorZhao, Linjing-
dc.contributor.authorFeng, Bo-
dc.contributor.authorHu, Xiaofang-
dc.contributor.authorXu, Lisa X.-
dc.contributor.authorZhao, Aihua-
dc.contributor.authorZhang, Menghui-
dc.contributor.authorCai, Guoxiang-
dc.contributor.authorCai, Sanjun-
dc.contributor.authorZhou, Zhanxiang-
dc.contributor.authorZheng, Minhua-
dc.contributor.authorZhang, Yan-
dc.contributor.authorJia, Wei-
dc.date.accessioned2024-04-17T07:03:53Z-
dc.date.available2024-04-17T07:03:53Z-
dc.date.issued2013-
dc.identifier.citationJournal of Proteome Research, 2013, v. 12, n. 6, p. 3000-3009-
dc.identifier.issn1535-3893-
dc.identifier.urihttp://hdl.handle.net/10722/342448-
dc.description.abstractRecent studies suggest that biofluid-based metabonomics may identify metabolite markers promising for colorectal cancer (CRC) diagnosis. We report here a follow-up replication study, after a previous CRC metabonomics study, aiming to identify a distinct serum metabolic signature of CRC with diagnostic potential. Serum metabolites from newly diagnosed CRC patients (N = 101) and healthy subjects (N = 102) were profiled using gas chromatography time-of-flight mass spectrometry (GC-TOFMS) and ultraperformance liquid chromatography quadrupole time-of-flight mass spectrometry (UPLC-QTOFMS). Differential metabolites were identified with statistical tests of orthogonal partial least-squares-discriminant analysis (VIP > 1) and the Mann-Whitney U test (p < 0.05). With a total of 249 annotated serum metabolites, we were able to differentiate CRC patients from the healthy controls using an orthogonal partial least-squares-discriminant analysis (OPLS-DA) in a learning sample set of 62 CRC patients and 62 matched healthy controls. This established model was able to correctly assign the rest of the samples to the CRC or control groups in a validation set of 39 CRC patients and 40 healthy controls. Consistent with our findings from the previous study, we observed a distinct metabolic signature in CRC patients including tricarboxylic acid (TCA) cycle, urea cycle, glutamine, fatty acids, and gut flora metabolism. Our results demonstrated that a panel of serum metabolite markers is of great potential as a noninvasive diagnostic method for the detection of CRC. © 2013 American Chemical Society.-
dc.languageeng-
dc.relation.ispartofJournal of Proteome Research-
dc.subjectcolorectal cancer-
dc.subjectdiagnostic markers-
dc.subjectmetabolomics/metabonomics-
dc.subjectserum metabolites-
dc.titleMetabonomics identifies serum metabolite markers of colorectal cancer-
dc.typeArticle-
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1021/pr400337b-
dc.identifier.pmid23675754-
dc.identifier.scopuseid_2-s2.0-84879388581-
dc.identifier.volume12-
dc.identifier.issue6-
dc.identifier.spage3000-
dc.identifier.epage3009-
dc.identifier.eissn1535-3907-
dc.identifier.isiWOS:000320298600057-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats